Allogeneic Mesenchymal Stromal Cells in Elderly Patients With Hip Fracture
Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Prospective, unicenter, randomized, open-label, single-dose, two-arms blinded assessor pilot
study. Thirty-two (32) elderly patients with hip fracture will be randomized to one of the
two treatment-arms (Xcel-MT-osteo-beta or Standard treatment) and be followed for 12 month
with the primary objective of safety. Secondary objectives are efficacy through axial
tomography and xRay, clinical efficacy and quality of life questionnaire.